Create New Share
Please enter the email address below of the person you would like to share this article with.
An email will be sent to the recipient with a link to this chosen article.
A source for healthcare professionals to access the latest data and information on the diagnosis, treatment and management of patients with gut related disorders
Leeds J et al. Clin Gastroenterol Hepatol 2010;8:433–438.
Diarrhoea and abdominal pain are common symptoms of irritable bowel syndrome (IBS), which can cause psychological stress and reduction in the quality of life in affected patients. It has been suggested that IBS may have other underlying pathologies. Early-stage pancreatic disease presents with similar symptoms to IBS and it is therefore possible that there is a clinical overlap between these two conditions.
This study looked at faecal elastase-1 (Fe-1) levels in 314 patients meeting the Rome II criteria for diarrhoea-predominant IBS (IBS-D). Levels of Fe-1 were less than 100 µg/g of stool in 6.1% of patients with IBS-D compared with none in a group of 105 patients with chronic diarrhoea (without IBS symptoms) nor in any of 95 control patients. Levels of Fe-1 less than 100 µg/g are indicative of pancreatic exocrine insufficiency.
To assess the effects of pancreatic enzyme supplementation, stool frequency, stool consistency and abdominal pain were recorded in two groups of patients; group 1 had IBS-D and Fe-1 levels less than 100 µg/g and group 2 (therapeutic controls) had IBS-D and Fe-1 levels greater than 200 µg/g.
A clinically significant response to therapy was observed in 94.7% (18 of 19) patients in group 1, compared with only 6.7% (1 of 15) in group 2. Significant improvements in stool frequency, stool consistency and abdominal pain were observed in patients in group 1, but not in
These results suggest that pancreatic exocrine insufficiency should be considered in patients referred from primary care with IBS-like symptoms. Where this is confirmed, pancreatic enzyme supplementation therapy may help to reduce diarrhoea and abdominal pain, and improve quality of life.
Job number: JB57410GBq Date of Preparation: June 2019
You must be registered to GutNews.org
to view or download these files
Brief report: length of ileal resection correlates with severity of bile acid malabsorption in Crohn’s disease
In patients with Crohn’s disease who had a prior surgical resection there was a modest correlation between the length of ileal resection and the severity of bile acid malabsorption (BAM), as defined by tauroselcholic (75selenium) acid (SeHCAT) retention values. Response to bile salt sequestrant therapy was not dependent on SeHCAT retention values.
Are you a healthcare professional?
This educational website is developed by GE Healthcare for educational purposes. The information contained within this website is intended for healthcare professionals. By entering this website you are confirming that you are a healthcare professional.
This link opens another website that is not under the review or control of GE Healthcare Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.